Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SERES THERAPEUTICS, INC.

(MCRB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/21/2021 07/22/2021 07/23/2021 07/26/2021 07/27/2021 Date
20.83(c) 7.95(c) 7.39(c) 7.68(c) 7.12(c) Last
872 360 13 431 706 11 057 023 2 468 587 2 154 606 Volume
+0.48% -61.83% -7.04% +3.92% -7.29% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 25,6 M - -
Net income 2021 -123 M - -
Net cash position 2021 172 M - -
P/E ratio 2021 -6,40x
Yield 2021 -
Sales 2022 104 M - -
Net income 2022 -97,6 M - -
Net cash position 2022 196 M - -
P/E ratio 2022 -7,91x
Yield 2022 -
Capitalization 653 M 653 M -
EV / Sales 2021 18,7x
EV / Sales 2022 4,40x
Nbr of Employees 155
Free-Float 90,9%
More Financials
Company
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics... 
More about the company
Ratings of Seres Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about SERES THERAPEUTICS, INC.
07/23SERES THERAPEUTICS : Oppenheimer Adjusts Seres Therapeutics PT to $18 From $36, ..
MT
07/23SERES THERAPEUTICS : Chardan Adjusts Price Target on Seres Therapeutics to $16 F..
MT
07/23SERES THERAPEUTICS : Canaccord Genuity Adjusts Seres Therapeutics' Price Target ..
MT
07/23SERES THERAPEUTICS : HC Wainwright Adjusts Seres Therapeutics' Price Target to $..
MT
07/23SERES THERAPEUTICS : Goldman Sachs Cuts Seres Therapeutics to Sell From Neutral,..
MT
07/22UPDATE : Seres Therapeutics Shares Dive 58% in Heavy Trading Volume After Ulcera..
MT
07/22SERES THERAPEUTICS' : SER-287 Fails to Meet Main Goal of Phase 2b Trial
MT
07/22SERES THERAPEUTICS : to Host Conference Call and Webcast to Discuss Topline Resu..
BU
07/22SERES THERAPEUTICS : Announces Topline Results for SER-287 Phase 2b Study in Mil..
PU
07/22SERES THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Ex..
AQ
07/22SERES THERAPEUTICS : Announces Topline Results for SER-287 Phase 2b Study in Mil..
BU
07/22Seres Therapeutics, Inc. Announces Topline Results from the Phase 2B ECO-RESE..
CI
07/02SERES THERAPEUTICS : Piper Sandler Adjusts Price Target on Seres Therapeutics to..
MT
07/01SERES THERAPEUTICS : Nestle Health Science Sign Commercialization Deal for Micro..
MT
07/01SERES THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
More news
News in other languages on SERES THERAPEUTICS, INC.
2020NESTLÉ : le titre surnage grâce à un relèvement de broker
More news
Analyst Recommendations on SERES THERAPEUTICS, INC.
More recommendations
Chart SERES THERAPEUTICS, INC.
Duration : Period :
Seres Therapeutics, Inc. Technical Analysis Chart | MCRB | US81750R1023 | MarketScreener
Technical analysis trends SERES THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 7,12 $
Average target price 21,14 $
Spread / Average Target 197%
EPS Revisions
Managers and Directors
Eric D. Shaff President, Chief Executive Officer & Director
David A. Arkowitz EVP, Chief Financial & Accounting Officer
Stephen A. Berenson Chairman
Matthew R. Henn Chief Scientific Officer & Executive VP
Barbara McGovern Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
SERES THERAPEUTICS, INC.-70.94%653
GILEAD SCIENCES, INC.18.31%86 563
BIONTECH SE248.38%69 138
WUXI APPTEC CO., LTD.28.80%67 035
REGENERON PHARMACEUTICALS20.26%59 833
VERTEX PHARMACEUTICALS-14.17%51 496